Risk Stratification of Sentinel Node Metastasis Disease Burden and Phenotype in Stage III Melanoma Patients

BACKGROUND: Currently, all patients with American Joint Committee on Cancer (AJCC) pT2b-pT4b melanomas and a positive sentinel node biopsy are now considered for adjuvant systemic therapy without consideration of the burden of disease in the metastatic nodes. METHODS: This was a retrospective cohort...

Descripción completa

Detalles Bibliográficos
Autores principales: Hussain, Zahra, Heaton, Martin J., Snelling, Andrew P., Nobes, Jenny P., Gray, Gill, Garioch, Jennifer J., Moncrieff, Marc D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Melanoma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908720/
https://www.ncbi.nlm.nih.gov/pubmed/36445500
http://dx.doi.org/10.1245/s10434-022-12804-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908720/
https://www.ncbi.nlm.nih.gov/pubmed/36445500
http://dx.doi.org/10.1245/s10434-022-12804-6

Ejemplares similares